Silexion Therapeutics Corp. has announced amendments to its bylaws following shareholder approval of a 1-for-15 reverse share split. Effective July 28, 2025, the company's ordinary shares will trade on a split-adjusted basis on Nasdaq. The reverse split, approved at the 2025 Annual General Meeting, decreases issued and outstanding shares while maintaining the authorized share capital at $20,000, adjusting the par value of shares from $0.0009 to $0.0135. The trading symbol "SLXN" remains unchanged.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.